Bellevue Group AG Purchases 4,614 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bellevue Group AG grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,956 shares of the medical research company’s stock after buying an additional 4,614 shares during the period. Bellevue Group AG’s holdings in Thermo Fisher Scientific were worth $23,223,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LifeSteps Financial Inc. bought a new position in Thermo Fisher Scientific during the first quarter worth about $31,000. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. True Wealth Design LLC boosted its holdings in Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after buying an additional 51 shares during the last quarter. Headlands Technologies LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $32,000. Finally, Pineridge Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $39,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMO. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Stifel Nicolaus lifted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday. HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Finally, Barclays dropped their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $12.64 during midday trading on Friday, hitting $607.14. 2,715,365 shares of the company’s stock were exchanged, compared to its average volume of 1,737,231. The company has a quick ratio of 1.33, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $614.65. The company’s 50 day moving average price is $563.01 and its 200 day moving average price is $565.97. The firm has a market capitalization of $231.76 billion, a PE ratio of 38.94, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $5.15 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.